Wednesday, August 20, 2014
   
Text Size

Site Search powered by Ajax

Articles

NanoVir Patent Filings

NanoVir’s Intellectual Property Portfolio
 
NanoVir is prosecuting patent applications in the U.S. and worldwide.  The first family entitled “Polyamides for Treating Human Papillomavirus” has pending applications in Japan (2009509753) and the U.S. (13/357,740, and 12/534,666) that claim methods and compositions for treating HPV.  Two patents have issued from this family:  U.S. 7,589,171 and 8,119,677, both claiming compositions for treating cells infected with papilloma virus.  Additionally, a patent has been granted in Europe claiming methods and compositions for treating HPV, EP2013200, that has been validated in Great Britain, Italy, Germany, Spain, and France.  They will expire March 9, 2027. 
 
A second family entitled “Polyamides for Treating Human Papillomavirus” has pending applications in the U.S. (13/357,740) and PCT (PCT/US13/23188).  These applications claim both compounds, compositions and methods for treating HPV.  Any patents that issue from these applications will expire January 25, 2032.
 
A third family of applications entitled “Guanidinyl-Substituted Polyamides Useful for Treating Human Papillomavirus” has pending applications in the U.S. (13/649,000) and PCT (PCT/US12/59604).  These applications claim both compositions and methods for treating HPV.  If issued, these will expire October 10, 2032.
 
 
The patents and pending applications are all assigned to NanoVir, LLC

Who's Online

We have 5 guests and no members online